2d agoSeeking AlphaBULLISH 55Product/PR
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow
2026-09-10. The following slide deck was published by Tyra Biosciences, Inc.
Archived explainer. For the current picture see today's TYRA page.
Why Is TYRA BIOSCIENCES INC (TYRA) Stock Up Today?
By the Top Tier Newswire AI Desk · September 11, 2026 at 12:10 AM ET · reviewed against 4 wire stories
TYRA BIOSCIENCES INC (TYRA) is up +6.95% in the latest session. Our newswire has captured 4 stories on TYRA across 3 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TYRA stock is up 6.95% today, closing at $23.54, following the release of initial data from its Phase 2 SURF302 trial for oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (NMIBC). The trial reported a 79% overall response rate (ORR) and a 64% best overall complete response rate at the 60 mg QD dose. The company identified this dose as the candidate for a potential Phase 3 adjuvant trial. These results contrast with earlier disappointing data from the intermediate risk NMIBC trial that caused a 20% drop in the stock.
What Happened
Tyra Biosciences released a slide deck on the initial results of its SURF302 study, which evaluated oral dabogratinib in low-grade intermediate risk NMIBC patients with FGFR3-altered tumors. The study reported a 79% ORR and a 64% best overall complete response rate at the 60 mg QD dose. The company also noted a 100% ORR in patients with a single marker lesion and highlighted the favorable safety profile of the drug. These findings are being positioned as a significant improvement over the earlier Phase 2 results, which had shown adverse events and missed the 70% complete response target.
H.C. Wainwright recently lowered its price target for TYRA to $30 from $45. Despite this, the stock has rebounded sharply on the latest data, signaling renewed investor interest in the company’s pipeline.
What The Data Shows
Over the last eight trading sessions, TYRA has declined 7.5% from $25.03 to $23.17. The stock closed today at $23.54, still below its 52-week high of $40.65 but above its 52-week low of $11.70. On September 10, the stock printed three fresh 52-week lows and 22 fresh 52-week highs. The move today was accompanied by a surge in social media chatter, with one recent post highlighting the 79% ORR and 64% complete response rate.
What To Watch
The company has not announced upcoming earnings, but coverage breadth and analyst reactions will be key to monitor. The evolving narrative around dabogratinib’s potential in NMIBC will likely remain a focal point for investors.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TYRA by the numbers
Last: $23.54Session: +6.95%7 sessions: -8.70%Coverage: 4 stories / 3 sourcesAI sentiment: 38/100 (bearish)Mkt cap: $1.6B52w: $11.70 to $40.65
The headlines behind the move
3d agoThe FlyBEARISH 34Analyst
Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright
3d agoSeeking AlphaBEARISH 28Earnings
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines
Tyra Biosciences' stock slid 20% after Phase 2 dabogratinib missed the 70% CR goal in IR NMIBC. Read the latest analysis on the TYRA stock here.
3d agoMarketWatchBEARISH 34Product/PR
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TYRA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TYRA move explainers: 2026-09-11 · 2026-09-10 · 2026-09-09 · 2026-09-08 · 2026-09-04